In addition, lenalidomide has shown to maintain the in vitro activity of CD23 CAR-T cells, preserve functional CAR T-CLL cell immune synapses, and improve the therapeutic efficacy of CD23 CAR-T cells in vivo (73). Here, FCER2 is linked to B-cell chronic lymphocytic leukemia.